PRRT2 and neoplasm: In conclusion, we have shown that dual inhibition of PKC + p53-MDM2 and PKC + mTORC1 are more efficacious than other previously tested combinations in UM, with striking tumor regression observed in several in vivo models after co-targeting of PKC and p53-MDM2.